To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.
Also called NCT05852431
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 369 participants
- Sponsor
- 89bio, Inc.
- Registry
-
NCT05852431 -
2023-503576-25-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Austria, Belgium, Bulgaria, Canada, Chile, Czechia, France, Georgia, Germany, Hungary, India, Italy, Latvia, Mexico, Poland, Puerto Rico, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05852431. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-15 (actual); primary completion 2025-07-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
- Acronym
- ENTRUST
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Pegozafermin
- Intervention (Drug)
- Placebo
- Lead sponsor
- 89bio, Inc.
Record details
- Record id
cardio:ct-nct05852431- Content hash
0e09e6f365423cf33e4f47ed4d4f8efaec7cbe28c756d8ca26b843bba43de3c1